Literature DB >> 22196477

Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Marc Miravitlles1, Myriam Calle, Juan José Soler-Cataluña.   

Abstract

The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes". Among all phenotypes described, there are three that are associated with prognosis and especially are associated with a different response to currently available therapies. There phenotypes are: the exacerbator, the overlap COPD-asthma and the emphysema-hyperinflation. The exacerbator is characterised by the presence of, at least, two exacerbations the previous year, and on top of long-acting bronchodilators, may require the use of antiinflammatory drugs. The overlap phenotype presents symptoms of increased variability of airflow and incompletely reversible airflow obstruction. Due to the underlying inflammatory profile, it uses to have a good therapeutic response to inhaled corticosteroids in addition to bronchodilators. Lastly, the emphysema phenotype presents a poor therapeutic response to the existing antiinflammatory drugs and long-acting bronchodilators together with rehabilitation are the treatments of choice. Identifying the peculiarities of the different phenotypes of COPD will allow us to implement a more personalised treatment, in which the characteristics of the patients, together with their severity will be key to choose the best treatment option. Copyright Â
© 2011 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22196477     DOI: 10.1016/j.arbres.2011.10.007

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  76 in total

Review 1.  Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Authors:  Sibel Atış Naycı; Lütfi Çöplü; Alev Gürgün; Nurdan Köktürk; Mehmet Polatlı; Elif Şen; Sema Umut; Esra Uzaslan; Nurhayat Yıldırım; Peter J Barnes
Journal:  Turk Thorac J       Date:  2015-04-01

Review 2.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

3.  The Challenges of Precision Medicine in COPD.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

4.  Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease.

Authors:  Cassie C Kennedy; Paul J Novotny; Nathan K LeBrasseur; Robert A Wise; Frank C Sciurba; Roberto P Benzo
Journal:  Ann Am Thorac Soc       Date:  2019-02

5.  [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Riesco; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; José Luis López-Campos; Joan B Soriano; Julio Ancochea
Journal:  Aten Primaria       Date:  2012-06-15       Impact factor: 1.137

6.  Imaging and COPD.

Authors:  Bruno Hochhegger
Journal:  J Bras Pneumol       Date:  2015 Nov-Dec       Impact factor: 2.624

Review 7.  Defining phenotypes in COPD: an aid to personalized healthcare.

Authors:  Andrea Segreti; Emanuele Stirpe; Paola Rogliani; Mario Cazzola
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

8.  The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda; Jordi Ibáñez-Nolla
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

9.  Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement.

Authors:  M Miravitlles; J J Soler-Cataluña; F Baranda; P Cordero; J-V Greses; C de la Roza
Journal:  Infection       Date:  2012-08-21       Impact factor: 3.553

10.  Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions.

Authors:  Mercè Mateu-Jiménez; Albert Sánchez-Font; Alberto Rodríguez-Fuster; Rafael Aguilό; Lara Pijuan; Clara Fermoselle; Joaquim Gea; Victor Curull; Esther Barreiro
Journal:  Mol Med       Date:  2016-01-07       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.